<DOC>
	<DOC>NCT00960258</DOC>
	<brief_summary>This study is to define the pharmacokinetics and to evaluate the safety of BAY73-4506, 160 mg once daily administered orally as a single agent in Japanese patients with advanced solid tumors.</brief_summary>
	<brief_title>Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.</brief_title>
	<detailed_description />
	<criteria>Male or female Japanese patients &gt;/= 18 years Histologically or cytologically confirmed solid tumors ECOGPS 0 1 Adequate bone marrow, liver and renal function Uncontrolled hypertension Patients with severe renal impairment or on dialysis Patients with seizure disorder requiring anticonvulsant medication Known or suspected allergy to the investigational agent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Solid Tumors</keyword>
</DOC>